Pasithea Therapeutics Corp. KTTA
0.53 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:20 PM EST
0.51 -0.02 -3.40%
After hours · Nov 4, 4:20 PM ET
0.4809 Day range 0.59
0.281 52-week range 2.06
- YTD
- -58.91%
- 1 year
- -30.99%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…
benzinga.com Pasithea Therapeutics Says FDA Clears IND Application For Randomized, Placebo-Controlled Phase 2 Clinical Trial For PAS-004 In Patients With NF1 Associated Cutaneous Neurofibromas — FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies.…
globenewswire.com Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF) — FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies . —…
globenewswire.com Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026 MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation…
benzinga.com Pasithea Therapeutics Presents Phase I Dose-Escalation Trial Of PAS-004 Inhibitor; Announces No Dose Limiting Toxicities Seen; No Participant Discontinued PAS-004; No Grade 3, Higher Observed Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced
globenewswire.com Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 -- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once…
defenseworld.net Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 2.7% – Time to Sell? Pasithea Therapeutics Corp. (NASDAQ: KTTA - Get Free Report) shares dropped 2.7% on Friday. The company traded as low as $0.4748 and last traded at $0.4760. Approximately 59,809 shares were traded…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million. Geovax Labs (NASDAQ:GOVX)…
benzinga.com Pasithea Sets November Debut For Early PAS-004 Clinical Trial Results Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term
globenewswire.com Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference - Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a…
globenewswire.com Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences -- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Picard Medical (AMEX:PMI) stock rose 40.2% to $4.5 during Friday's after-market session. The company's market cap stands at $6.2 million. As per the news, the Q2 earnings report came out 2…
defenseworld.net Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA) Oncobiologics (NASDAQ: OTLK - Get Free Report) and Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast…
benzinga.com Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026 -- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be…
globenewswire.com Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 -- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be…
zacks.com New Strong Buy Stocks for July 20th KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2026.
globenewswire.com Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation…- benzinga.com Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2 Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term
globenewswire.com Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion -- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal…
benzinga.com HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $3 price target.
benzinga.com Pasithea Therapeutics Amends Clinical Study Protocol For Phase 1/1b Trial Of PAS-004 In Neurofibromatosis Type 1 Patients With Symptomatic Inoperable, Incompletely Resected, Or Recurrent Plexiform Neurofibroma -- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and longer treatment period added --MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp.…
globenewswire.com Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial -- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics…
globenewswire.com Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference -- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with…
zacks.com Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Pasithea Therapeutics (KTTA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong…- benzinga.com Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophic Lateral Sclerosis Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that…
globenewswire.com Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation…- benzinga.com Pasithea Therapeutics Corp. Receives FDA Orphan Drug Designation For MEK1/2 Inhibitor For Treatment Of Amyotrophic Lateral Sclerosis https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145326
globenewswire.com Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
globenewswire.com Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation…
defenseworld.net Pasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on Monday Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) is projected to announce its results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.18)…
seekingalpha.com Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Vision Marine Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Crude Oil Gains 1%; Tilray Brands Shares Plunge 
benzinga.com Nasdaq Rises 100 Points; Chagee Shares Gain After Q3 Results - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Nasdaq Jumps Over 100 Points; Deere Shares Fall After Q4 Results - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session